Pan-cancer transcriptomic profiling recognises butyrophylin protein BTN3A3 as an immune-associated cancer biomarker

Cancer remains a significant global health burden with increasing mortality and incidence rates, particularly in middle and lower-income countries. A butyrophilin protein subfamily member BTN3A3, expressed by immune modulatory cells participates in T-cell activation and immune surveillance. We performed a comprehensive expression analysis of BTN3A3 and other members of the subfamily in a stage-wise manner across various cancers. The differential expression analysis reveals a common pattern of downregulation among various cancers. A cross-cancer comparative analysis of BTN3A1, BTN3A2 and BTN3A3 genes revealed a comparable trend of downregulation; whereas BTN3A3 exhibited more pronounced downregulation in Breast Invasive carcinoma, Lung Adenocarcinoma and Liver Hepatocellular carcinoma, than its other two subfamily members. Additionally, stage-specific methylation analysis of BTN3A3 revealed a constant pattern of hypermethylation in the promoter region and hypomethylation within the gene body across three cancers. Gene ontology analysis revealed immune regulatory genes such as TLR4, CD36, CCL11, IL34, growth factors like HGF that share similar pathways, along with a hypomethylation pattern similar to BTN3A3. The expression, regulation and epigenetic patterns of PPI network genes include immune regulatory genes such as LTF, HLA-F, and CD1D support BTN3A3’s role in immune surveillance of the cancer microenvironment. Gene cluster analysis revealed co-expression of BTN3A3 gene with genes, having versatile functions including immune regulation (PAG1, TRAV39, HLA-DQB1, MS4A2, PARP14, POLR3B), tumor suppression (IL6ST), transcription (ETS1, KLF3, NFIA), cell signalling (GPCRs- AGRT2, OR6S1; signalling kinases- MAP3K2, MET, CAMK2D, STK33, TGFBR1). Collectively, this integrated finding suggests a gradual downregulation of BTN3A3 expression over advanced stage cancer progression, underscoring its significance as a potential prognostic biomarker for metastatic stage cancers.

Authors

Institutions

Publication Details

Journal
Discover Oncology
Published
2026-11-17
DOI
https://doi.org/10.1007/s12672-026-06094-7
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pan-cancer transcriptomic profiling recognises butyrophylin protein BTN3A3 as an immune-associated cancer biomarker

Krishna Sayantika Deb, Rahul Shaw, Kuntal Pal
1 links
Discover Oncology
Cancer Immunotherapy and Biomarkers
article

Pan-cancer transcriptomic profiling recognises butyrophylin protein BTN3A3 as an immune-associated cancer biomarker

Krishna Sayantika Deb, Rahul Shaw, Kuntal Pal
article en

Abstract

Cancer remains a significant global health burden with increasing mortality and incidence rates, particularly in middle and lower-income countries. A butyrophilin protein subfamily member BTN3A3, expressed by immune modulatory cells participates in T-cell activation and immune surveillance. We performed a comprehensive expression analysis of BTN3A3 and other members of the subfamily in a stage-wise manner across various cancers. The differential expression analysis reveals a common pattern of downregulation among various cancers. A cross-cancer comparative analysis of BTN3A1, BTN3A2 and BTN3A3 genes revealed a comparable trend of downregulation; whereas BTN3A3 exhibited more pronounced downregulation in Breast Invasive carcinoma, Lung Adenocarcinoma and Liver Hepatocellular carcinoma, than its other two subfamily members. Additionally, stage-specific methylation analysis of BTN3A3 revealed a constant pattern of hypermethylation in the promoter region and hypomethylation within the gene body across three cancers. Gene ontology analysis revealed immune regulatory genes such as TLR4, CD36, CCL11, IL34, growth factors like HGF that share similar pathways, along with a hypomethylation pattern similar to BTN3A3. The expression, regulation and epigenetic patterns of PPI network genes include immune regulatory genes such as LTF, HLA-F, and CD1D support BTN3A3’s role in immune surveillance of the cancer microenvironment. Gene cluster analysis revealed co-expression of BTN3A3 gene with genes, having versatile functions including immune regulation (PAG1, TRAV39, HLA-DQB1, MS4A2, PARP14, POLR3B), tumor suppression (IL6ST), transcription (ETS1, KLF3, NFIA), cell signalling (GPCRs- AGRT2, OR6S1; signalling kinases- MAP3K2, MET, CAMK2D, STK33, TGFBR1). Collectively, this integrated finding suggests a gradual downregulation of BTN3A3 expression over advanced stage cancer progression, underscoring its significance as a potential prognostic biomarker for metastatic stage cancers.

Discover Oncology
Vellore Institute of Technology University (IN)
VIT University
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon